Skip to main content
. Author manuscript; available in PMC: 2015 Mar 14.
Published in final edited form as: Vaccine. 2013 Nov 16;32(13):1495–1500. doi: 10.1016/j.vaccine.2013.11.032

Figure 3.

Figure 3

F protein vaccine formulated with MPL increased neutralizing antibody titers against RSV, and reduced lung viral replication and histopathology. Cotton rats were vaccinated with F+MPL (at 15 and 50 μg/rat) i.n., followed by i.d. boosting 21 days later. Control animals were PBS-vaccinated (M, naïve animals), or infected with RSV i.n. (RSV). An additional control was included that corresponded to animals vaccinated twice i.m. with the FI-RSV vaccine Lot 100 in a dilution of 1:125. All animals were challenged with RSV/A Long 48 days after the first vaccination. (A) RSV neutralization antibody titers from sera obtained before challenge (day 48). (B) Viral titers of lung and nose obtained 4 days post-challenge (peak viral replication). (C) RSV F protein gene expression in lungs of animals challenged on day 48 with RSV/A Long. Significant differences in the expression are detected on day 4 and day 6 post challenge. (D) Lung histopathology scores on day 6 post-RSV challenge (peak lung pathology). Scores of interstitial pneumonia and alveolitis are blunted in animals vaccinated with F+MPL (arrows).